Abstract:To investigate whether tumor cell lysate-pulsed (TP) dendritic cells (DCs) induce cytotoxic T lymphocyte (CTL) activity against colon cancer in vitro and in vivo . Hematopoietic progenitor cells were magnetically isolated from BALB/c mice bone marrow cells. These cells were cultured with cytokines GM-CSF, IL-4, and TNFα to induce their maturation. They were analyzed by morphological observation and phenotype analysis. DCs were pulsed with tumor cell lysate obtained by rapid freezing and thawing at a 1:3 DC:tumor cell ratio. CTL activity and interferon gamma (IFNγ) secretion was evaluated ex vivo. In order to determine whether or not vaccination with CT26 TP DCs induce the therapeutic potential in the established colon tumor model, CT26 colon tumor cells were implanted subcutaneously (s.c.) in the midflank of naïve BALB/c mice. Tumor-bearing mice were injected with vaccination with CT26 TP DCs on days 3 and 10. Tumor growth was assessed every 2–3 days. Finally, CTL activity and IFNγ secretion were evaluated in immunized mice. Hematopoietic progenitor cells from mice bone marrow cells cultured with cytokines for 8 days showed the character of typical mature DCs. Morphologically, these cells were large with oval or irregularly shaped nuclei and with many small dendrites. Phenotypically, FACS analysis showed that they expressed high levels of MHC II, CD11b, CD80, and CD86 antigen, and were negative for CD8α. However, immature DCs cultured with cytokines for 5 days did not have typical DCs phenotypic markers. Ex vivo primed T cells with CT26 TP DCs were able to induce effective CTL activity against CT26 tumor cells, but not B16 tumor cells ( E : T = 100:1, 60.36 ± 7.11% specific lysis in CT26 group vs. 17.36 ± 4.10% specific lysis in B16 group), and produced higher levels of IFNγ when stimulated with CT26 tumor cells but not when stimulated with B16 tumor cells (1210.33 ± 72.15 pg/ml in CT26 group vs. 182.25 ± 25.51 pg/ml in B16 group, P < 0.01). Vaccination with CT26 TP DCs could induce anti-tumor immunity against CT26 colon tumor in murine therapeutic models (tumor volume on day 19: CT26 TP DCs 342 ± 55 mm 3 vs. the other control groups, P < 0.05). In addition, all splenic CD3 + T cells obtained from mice vaccinated with CT26 TP DCs produced high levels of IFNγ and shown specific cytotoxic activity against CT26 tumor cells, but no cytotoxic activity when stimulated with B16 tumor cells. Tumor cell lysate-pulsed DCs can induce tumor-specific CTL activity against colon cancer in vitro and in vivo .

Dendritic Cells Loaded with CD44+ CT-26 Colon Cell Lysate Evoke Potent Antitumor Immune Responses.

Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo

Dendritic Cell-Targeting Chemokines Inhibit Colorectal Cancer Progression

Therapeutic Antitumor Efficacy of Cancer Stem Cell-Derived DRibble Vaccine on Colorectal Carcinoma

Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells

Synergistical Toll-Like Receptors Activated Dendritic Cells Induce Antitumor Effects Against Carcinoembryonic Antigen-Expressing Colon Cancer

In Vitro Antitumor Immune Response Induced By Fusion Of Dendritic Cells And Colon Cancer Cells

Dendritic cells with synergistte activation of Toll-like receptor ligands induce antitumor effects against colon cancer in vitro

Allogeneic Dendritomas Induce Anti‐tumour Immunity Against Metastatic Colon Cancer

Dendritic cell/tumor hybrids enhance therapeutic efficacy against subcutaneously implanted colon cancer in severe combined immunodeficient mice

In vitro study on the efficiency of anti-colon cancer effect of CD40L pulsed DC-based vaccine

Dendritic Cells Based Immunotherapy

Dendritic Cells-Mediated CTLs Targeting Hepatocellular Carcinoma Stem Cells

Superior Efficacy of Dendritic Cell-Tumor Fusion Vaccine Compared with Tumor Lysate-Pulsed Dendritic Cell Vaccine in Colon Cancer

Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells

Anti-tumor Activity of Dendritic Cells Loading in Situ Tumor Lysate Antigen Proudced by Radiofrequency Ablation

Dendritic Cells Vaccines Activated by Combined Toll-like Receptor Llgands Inhibit Murine Colon Cancer in Vivo

Increase of the Immunostimulatory Effect of Dendritic Cells by Pulsing With CA 19-9 Protein

Selective Colorectal Cancer Cell Lysates Enhance the Immune Function of Mature Dendritic Cells in Vitro.

CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro

Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice.